KRAS and non-small cell lung carcinoma: Kutkowska et al. also found inhibitory synergistic effects when using sorafenib in combination with betulinic acid in three NSCLC lines with different KRAS mutations: A549 (KRASG12S), H358 (KRASG12C), and A427 (KRASG12D) [36].